Oral administration of immunopotentiator from pantoea agglomerans 1 (IP-PA1) improves the survival of B16 melanoma-inoculated model mice

Experimental Animals

Volumn 60, Issue 2, 2011, Pages 101-109

  Hebishima, Takehisa ^a,b,e   Matsumoto, Yasunobu ^b   Watanabe, Gen ^a,e   Soma, Gen Ichiro ^c,d   Kohchi, Chie ^c,d   Taya, Kazuyoshi ^a,e   Hayashi, Yoshihiro ^b   Hirota, Yoshikazu ^a,e  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^d KAGAWA UNIVERSITY   (Japan)

^e GIFU UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Immunomodulator; Immunosuppression; IP PA1; Melanoma

Indexed keywords

DOXORUBICIN; GAMMA INTERFERON; IMMUNOMODULATING AGENT; IMMUNOPOTENTIATOR FROM PANTOEA AGGLOMERANS 1; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CD4 CD8 RATIO; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA B16; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN BLOOD LEVEL; SURVIVAL TIME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-CD8 RATIO; CELL PROLIFERATION; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; INTERFERON-GAMMA; INTERLEUKIN-12; KILLER CELLS, NATURAL; LIPOPOLYSACCHARIDES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PANTOEA; SKIN NEOPLASMS; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA;

MUS; PANTOEA AGGLOMERANS;

EID: 79955454117     PISSN: 13411357     EISSN: None     Source Type: Journal    
DOI: 10.1538/expanim.60.101     Document Type: Article

References (44)

1. Adolf, G.R. 1985. Structure and effects of interferon-gamma. Oncology 42: S33-40.
2. Aebersold, P., Hyatt, C., Johnson, S., Hines, K., Korcak, L., Sanders, M., Lotze, M., Topalian, S., Yang, J., and Rosenberg, S.A. 1991. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J. Natl. Cancer Inst. 83: 932-937.
3. Akira, S. and Takeda, K. 2004. Toll-like receptor signaling. Nat. Rev. Immunol. 4: 499-511.
4. Angele, M.K. and Chaudry, I.H. 2005. Surgical trauma and immunosuppression: pathophysiology and potential immunomodulatory approaches. Langenbecks Arch. Surg. 390: 333-341.
5. Atallah, E. and Flaherty, L. 2005. Treatment of metastatic malignant melanoma. Curr. Treat. Options Oncol. 6: 185-193.
6. Berwick, M. and Wiggins, C. 2006. The current epidemiology of cutaneous malignant melanoma. Front. Biosci. 11: 1244-1254.
7. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature 420: 885-891.
8. Dominguez-Rodriguez, J.R., Chaparro-Huerta, V., Hernandez-Flores, G., Gomez-Contreras, P.C., Lerma-Diaz, J.M., Ortiz-Lazareno, P.C., Cervantes-Munguia, R., Orbach-Arbouys, S., Scott-Algara, D., and Cuellar, A.B. 2004. In vivo adriamycin-induced apoptosis in peritoneal murine macrophages: partial participation of a caspase cascade. Anticancer Res. 24: 2689-2696.
9. Dummer, W., Bastian, B.C., Ernst, N., Schänzle, C., Shawaaf, A., and Bröcker, E.B. 1996. Interleukini-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int. J. Cancer 66: 607-610.
10. Eton, O., Legha, S.S., Moon, T.E., Buzaid, A.C., Papadopoulos, N.E., Plager, C., Burgess, A.M., Bedikian, A.Y., Ring, S., Dong, Q., Glassman, A.B., Balch, C.M., and Benjamin, R.S. 1998. Prognostic factor for survival of patients treated systemically for disseminated melanoma. J. Clin. Oncol. 16: 1103-1111.
11. Gadd, M.A., Cosimi, A.B., Yu, J., Duncan, L.M., Yu, L., Flotte, T.J., Souba, W.W., Ott, M.J., Wong, L.S., Sober, A.J., Mihm, M.C., Haluska, F.G., and Tanabe, K.K. 1999. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch. Surg. 134: 381-387.
12. Gidlund, M., Orn, A., Pattengale, P.K., Jansson, M., Wigzell, H., and Nilsson, K. 1981. Natural killer cells kill tumor cells at a given stage of differentiation. Nature 292: 848-850.
13. Haller, O., Hansson, M., Kiessling, R., and Wigzell, H. 1977. Role of non-conventional natural killer cells in resistance against syngeneic tumor cells in vivo. Nature 270: 609-611.
14. Hebishima, T., Matsumoto, Y., Soma, G.I., Kohchi, C., Watanabe, G., Taya, K., Hayashi, Y., and Hirota, Y. 2010. Immune recovery effects of Immunopotentiator from Pantoea agglomerans 1 (IP-PA1) on low antibody productions in response to Salmonella enteritidis vaccine and sheep red blood cells in dexamethasone-treated stressed chicken models. J. Vet. Med. Sci. 72: 435-442.
15. Hebishima, T., Matsumoto, Y., Soma, G.I., Kohchi, C., Watanabe, G., Taya, K., Hayashi, Y., and Hirota, Y. 2010. Protective effects of Immunopotentiator from Pantoea agglomerans 1 on chemotherapeutic agent-induced macrophage growth inhibition. Anticancer Res. 30: 2033-2040.
16. Hu, F. and Lesney, P.F. 1964. The isolation and cytology of two pigment cell strains from B16 mouse melanomas. Cancer Res. 24: 1634-1643.
17. Inagawa, H., Nishizawa, T., Tsukioka, D., Suda, T., Chiba, Y., Okutomi, T., Morikawa, T., Soma, G.I., and Mizuno, D. 1992. Homeostasis as regulated by activated macrophage. II. LPS of plant origin other than wheat flour and their concomitant bacteria. Chem. Pharm. Bull. 40: 994-997.
18. Inagawa, H., Nishizawa, T., Yoshioka, N., Taniguchi, Y., Kohchi, C., and Soma, G.I. 2008. Preventive and therapeutic of lipopolysaccharide derived from edible Gram-negative bacteria to various diseases. Curr. Drug Therapy 3: 26-32.
19. Jemal, A., Devesa, S.S., Hartge, P., and Tucker, M.A. 2001. Recent trends in cutaneous melanoma incidence among whites in the United States. J. Cancer Inst. 93: 678-683.
20. Kohchi, C., Inagawa, H., Nishizawa, T., Yamaguchi, T., Nagai, S., and Soma, G.I. 2006. Applications of lipopolysaccharide derived from Pantoea agglomerans (IP-PA1) for health care based on macrophage network theory. J. Biosci. Bioeng. 102: 485-496.
21. Kripke, M.L. 1994. Ultraviolet radiation and immunology: something new under the sun-presidential address. Cancer Res. 54: 6102-6105.
22. Kuphal, S. and Bosserhoff, A. 2009. Recent progress in understanding the pathology of malignant melanoma. J. Pathol. 219: 400-409.
23. Kuroda, E., Sugiura, T., Zeki, K., Yoshida, Y. and Yamashita, U. 2000. Sensitivity difference to the suppressive effect of prostaglandin E2 among mouse strains: a possible mechanism to polarize Th2 type response in BALB/c mice. J. Immunol. 164: 2386-2395.
24. Lundy, J. and Ford, C.M. 1983. Surgery, trauma and immune suppression. Ann. Surg. 197: 434-438.
25. Mackall, C.L., Fleisher, T.A., Brown, M.R., Magrath, I.T., Shad, A.T., Horowitz, M.E., Wexler, L.H., Adde, M.A., McClure, L.L., and Gress, R.E. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84: 2221-2228.
26. Markovic, S.N., Erickson, L.A., Rao, R.D., Weenig, R.H., Pockaj, B.A., Bardia, A., Vachon, C.M., Schild, S.E., McWilliams, R.R., Hand, J.L., Laman, S.D., Kottschade, L.A., Maples, W.J., Pittelkow, M.R., Pulid, J.S., Cameron, J.D., and Creagan, E.T. 2007. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin. Proc. 82: 364-380.
27. Nishizawa, T., Inagawa, H., Oshima, H., Okutomi, T., Tsukioka, D., Iguchi, M., Soma, G.I., and Mizuno, D. 1992. Homeostasis as regulated by activated macrophage. I. Lipopolysaccharide (LPS) from wheat flour: isolation, purification and some biological activities. Chem. Pharm. Bull. 40: 479-483.
28. Restifo, N.P., Spiess, P.J., Karp, S.E., Mulé, J.J., and Rosenberg, S.A. 1992. A nonimmunogenic sarcoma transduced with the cDNA for interferon? elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J. Immunol. 175: 1423-1431.
29. Sato, N., Hirohashi, Y., Tsukahara, T., Kikuchi, T., Sahara, H., Kamiguchi, K., Ichimiya, S., Tamura, Y., and Torigoe, T. 2009. Molecular pathological approaches to humor tumor immunology. Pathol. Int. 59: 205-217.
30. Savill, J., Fadok, V., Henson, P., and Haslett, C. 1993. Phagocyte recognition of cells undergoing apoptosis. Immunol. Today 14: 131-136.
31. Sondel, P.M., Kohler, P.C., Hank, J.A., Moore, K.H., Rosenthal, N.S., Sosman, J.A., Bechhofer, R., and Storer, B. 1988. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res. 48: 2561-2567.
32. Suzuki, Y., Kobayashi, A., Nishizawa, T., Inagawa, H., Morikawa, A., Soma, G.I., and Mizuno, D. 1992. Homeostasis as regulated by activated macrophage. VI. Protective effects of LPSw (a lipopolysaccharide from wheat flour) against acute infection by Toxoplasma gondii in mice. Chem. Pharm. Bull. 40: 1266-1267.
33. Takano, R., Nose, M., Kanno, H., Nishihira, T., Hiraizumi, S., Kobata, A., and Kyogoku, M. 1990. Recognition of N-glycosidic carbohydrates on esophageal carcinoma cells by macrophages cell line THP-1. Am. J. Pathol. 137: 393-401.
34. Taniguchi, Y., Nishizawa, T., Honda, T., Yoshioka, N., Inagawa, H., Kohchi, C., and Soma, G.I. 2007. Development and potential use of a monoclonal antibody to the lipopolysaccharide of Pantoea agglomerans (IP-PA1). Anticancer Res. 27: 3701-3706.
35. Taniguchi, Y., Yoshioka, N., Nishizawa, T., Inagawa, H., Kohchi, C., and Soma, G.I. 2009. Utility and safety of LPS-based fermented flour extract as a macrophage activator. Anticancer Res. 29: 859-864.
36. Taniyama, T. and Holden, H.T. 1979. Requirement of histocompatible macrophages for the induction of a secondary cytotoxic response to syngeneic tumor cells in vitro. J. Immumol. 123: 43-49.
37. Tsao, H., Atkins, M.B., and Sober, A.J. 2004. Management of cutaneous melanoma. N. Engl. J. Med. 351: 998-1012.
38. Tsung, K., Dolan, J.P., Tsung, Y.L., and Norton, J.A. 2002. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res. 62: 5069-5075.
39. Utsugi, T., Schroit, A.J., Connor, J., Bucana, C.D., and Fidler, I.J. 1991. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 51: 3062-3066.
40. Voll, R.E., Herrmann, M., Roth, E.A., Stach, C., and Kalden, J.R. 1997. Immunosuppressive effects of apoptotic cells. Nature 390: 350-351.
41. Weinberg, J.B. and Larrick, J.W. 1987. Receptor-mediated monocytoid differentiation of human promyelocytic cells by tumor necrosis factor: synergistic actions with interferon-? and 1,25-dihydroxyvitamin D3. Blood 70: 994-1002.
42. Winkelhake, J.L., Stampfl, S., and Zimmerman, R.J. 1987. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models. Cancer Res. 47: 3948-3953.
43. Zimmermann, V.S., Benigni, F., and Mondino, A. 2005. Immune surveillance and anti-tumor immune responses: an anatomical perspective. Immunol. Lett. 98: 1-8.
44. Zitvogel, L., Apetoh, L., Ghiringhelli, F., and Kroemer, G. 2008. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8: 59-73.